Search Articles

View query in Help articles search

Search Results (1 to 10 of 86 Results)

Download search results: CSV END BibTex RIS

CSV download: Download all 86 search results (up to 5,000 articles maximum)

DermaDashboard: Bridging the Gap Between FHIR Standards and Clinical Usability

DermaDashboard: Bridging the Gap Between FHIR Standards and Clinical Usability

Demonstrated using patients with melanoma, the architecture is modular and generalizable to other diseases. This viewpoint provides a technical overview of the development pipeline, highlighting how FHIR-based data infrastructures can support the development of accessible, standards-driven dashboards in clinical environments. FHIR represents health care data as modular resources, each capturing specific clinical information which are linked via unique identifiers [15].

Katarzyna Borys, Eva Maria Hartmann, Ahmad Idrissi-Yaghir, Elisabeth Livingstone, Georg Lodde, Cynthia Sabrina Schmidt, Philipp Winnekens, Christoph M Friedrich, René Hosch, Felix Nensa

JMIR Cancer 2025;11:e73691


Deep Learning Multi-Modal Melanoma Detection: Algorithm Development and Validation

Deep Learning Multi-Modal Melanoma Detection: Algorithm Development and Validation

Incidence rates of melanoma have been on an increase since 1999, with 15.1 per 100,000 in 1999 and rising to 23.0 per 100,000 in 2021 [1]. In contrast, seborrheic keratosis is a benign skin appearance that commonly occurs in older adults. While the pathology, epidemiology, and histology of melanoma and seborrheic keratosis are well understood [2, 3, 4, 5], on a surface level, these 2 lesions can seem almost identical to the untrained eye, making it difficult for individuals to know when to seek care [6].

Nithika Vivek, Karthik Ramesh

JMIR AI 2025;4:e66561


Exploring the Views of Dermatologists, General Practitioners, and Melanographers on the Use of AI Tools in the Context of Good Decision-Making When Detecting Melanoma: Qualitative Interview Study

Exploring the Views of Dermatologists, General Practitioners, and Melanographers on the Use of AI Tools in the Context of Good Decision-Making When Detecting Melanoma: Qualitative Interview Study

Using AI for these purposes may improve the efficiency of melanoma detection and increase population access to dermatological assessment, particularly as improvements in the precision of imaging technology and convolutional neural networks allow for more machine autonomy in decision-making, thereby changing or creating new clinical paradigms in melanoma detection.

Brad Partridge, Nicole Gillespie, H Peter Soyer, Victoria Mar, Monika Janda

JMIR Dermatol 2025;8:e63923


Evaluating the Diagnostic Accuracy of ChatGPT-4 Omni and ChatGPT-4 Turbo in Identifying Melanoma: Comparative Study

Evaluating the Diagnostic Accuracy of ChatGPT-4 Omni and ChatGPT-4 Turbo in Identifying Melanoma: Comparative Study

Minimal research exists on Chat GPT’s accuracy in detecting melanoma. Given that patients are increasingly presenting internet-derived diagnostics during cancer consultations, it is imperative to understand the capabilities of commonly used AI engines, such as Chat GPT [4]. In this study, we compare the capabilities of two models—Chat GPT-4 Omni (GPT-4o) and Chat GPT-4 Turbo (GPT-4 Turbo)—in identifying melanoma versus “not melanoma” skin lesions.

Samantha S. Sattler, Nitin Chetla, Matthew Chen, Tamer Rajai Hage, Joseph Chang, William Young Guo, Jeremy Hugh

JMIR Dermatol 2025;8:e67551


User and Developer Views on Using AI Technologies to Facilitate the Early Detection of Skin Cancers in Primary Care Settings: Qualitative Semistructured Interview Study

User and Developer Views on Using AI Technologies to Facilitate the Early Detection of Skin Cancers in Primary Care Settings: Qualitative Semistructured Interview Study

Members of the public with a history of skin cancer were included in the patient group, with additional patients approached via Melanoma Focus (a UK melanoma charity that provides information, guidance, and support for patients, carers, and HCPs) [16]. GPs and primary care NPs were identified through the Primary Care Dermatology Society [17], with additional GPs approached via Sermo (medical market-research organization) [18].

Owain Tudor Jones, Natalia Calanzani, Suzanne E Scott, Rubeta N Matin, Jon Emery, Fiona M Walter

JMIR Cancer 2025;11:e60653


Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study

Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study

A secondary objective of the study is to assess any agreements or differences in the results of our wide range of participants in the usability studies, considering the target population of our e Health intervention (patients with melanoma and renal cell carcinoma treated with immunotherapy) and participants that are part of a broader population (patients with cancer with other types of cancer and informal caregivers).

Savannah Lucia Caterina Glaser, Itske Fraterman, Noah van Brummelen, Valentina Tibollo, Laura Maria Del Campo, Henk Mallo, Sofie Wilgenhof, Szymon Wilk, Vitali Gisko, Vadzim Khadakou, Ronald Cornet, Manuel Ottaviano, Stephanie Medlock

JMIR Form Res 2025;9:e57659


Exploring Motives Behind Ideal Melanoma Survivorship Care Plans With Multiple Stakeholders: A Cocreation Study

Exploring Motives Behind Ideal Melanoma Survivorship Care Plans With Multiple Stakeholders: A Cocreation Study

In recent years, the prognosis of melanoma, one of the most aggressive forms of skin cancer, has significantly improved due to advancements in innovative treatments such as immunotherapy and targeted therapy [1]. With an estimated worldwide total of 325,000 new cases in 2022, increasing to an expected total of 510,000 new cases in 2040 [2], this results in an expanding cohort of melanoma survivors, ie, individuals living with or beyond melanoma [3].

Nadia Christina Willemina Kamminga, Marjolein Lugtenberg, Julia Annabel Van den Broek, Tamar Nijsten, Marlies Wakkee, Kasia Tabeau

JMIR Cancer 2025;11:e55746